PENNY GREAVES: Open Payments
NPI 1710420807 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,893 in 36 payments from 8 companies in 2025. Trend: 2023 $83 · 2024 $400 · 2025 $1,893
Food & beverage: $1,431Consulting: $463
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 17 | $856 |
| Axsome Therapeutics, Inc. | 5 | $296 |
| Neurocrine BioSciences, Inc. | 2 | $279 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $192 |
| Alkermes, Inc. | 4 | $145 |
| Lundbeck LLC | 2 | $50 |
| Janssen Pharmaceuticals, Inc | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 1 | $31 |
Products named: COBENFY, Auvelity, INGREZZA, CAPLYTA, LYBALVI, REXULTI, INVEGA SUSTENNA, ARISTADA.
Industry payments across CA — which companies pay providers there.
